Pancreatic carcinoma
Conditions
Interventions
Experimental group:Gold Fiducial Implantation
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Written informed consent signed by the patient or the person authorized by the patient; 2. Aged >= 18 years; 3. The patient was diagnosed as pancreatic cancer by pathology; 4. The patient was to receive stereotactic radiotherapy for pancreatic cancer; 5. Patients can tolerate anesthesia; 6. The ECOG PS score was 0-2; 7. Estimated survival time >=3 months; 8. Laboratory results during screening must meet the following requirements: (1) Blood routine: absolute neutrophil count (ANC) >= 1.5 x 10^9/L, platelet count (PLT) > 50 x 10^9/L, hemoglobin (HGB) >= 90 g/L (no blood transfusion or erythropoietin dependence within 7 days); (2) Liver function: total bilirubin (TBIL) =60 mL/min (Cockcroft-Gault formula), and urine routine test results showed urinary protein (UPRO) < 2+ or 24-hour urinary protein quantification <1g; (4) Within 7 days before treatment, international normalized ratio (INR) <=1.5 times ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (APTT) <=1.5 times ULN; 9. Female patients of reproductive age should have a negative urine or serum pregnancy test within 3 days prior to receiving the first study drug administration (cycle 1, day 1). If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is requested; 10. Compliance with the study protocol is expected to be good.
Exclusion criteria
Exclusion criteria: 1. No suitable puncture path; 2. Patients with severe bleeding tendency, such as prothrombin time >18s, prothrombin activity <40%, and anticoagulant therapy and/or antiplatelet coagulation drugs stopped for less than 1 week before seed implantation therapy; 3. Unwell controlled serious comorbidities (such as severe hypertension, diabetes, etc.) leading to clinical risk; 4. Patients with active infectious diseases, trauma, stroke and severe trauma; 5. Patients with mental disorders; 6. Lactating patients; 7. Other researchers consider it inappropriate to be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| success rate;the optimal time interval between gold fiducial implantation and CT simulation; | — |
Countries
China
Contacts
Public ContactWang Junjie
Outcome results
None listed